Media

Proactive reports on the outlook of the oncology therapeutics market, naming Race Oncology, alongside its peer companies, one of the most promising to look out for. Read the full article via this link.

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. In this episode, Fraser Palamara takes a look at Race Oncology (ASX:RAC). Watch the video via this link

Race Oncology is reformulating bisantrene (RAC-220) to prevent chemotherapy-induced heart damage, with a phase 1 cardioprotection trial planned for early 2025. The trial will enroll 25-40 patients across multiple sites. The company has also reported promising results from a phase 1b/2 trial using the original bisantrene formulation (RC-110) in treating acute myeloid leukemia.  Read the…

As seen in The Australian, Dr Megan Baldwin joins the Race board as Non-Executive Director. Dr Baldwin is a seasoned biotech executive with more than 25 years of experience. She is the Founder and Chief Innovation Officer at Opthea Limited (ASX:OPT; NASDAQ:OPT), a late-stage biopharmaceutical company developing a novel therapy to address the unmet need…

Proactive reports on Race’s R&D tax rebate and clinical progress made in FY 2024. Read the full article here.

Conducted in two stages, the Phase 1 clinical trial will examine the safety and tolerability of the reformulated bisantrene, RC220, in particular the drug’s cardioprotective ability when used in combination with doxorubicin, a form of anthracycline commonly used in chemotherapy. The ethics submission is a milestone after a year’s preparation, with the first patient recruitment…

Race Oncology Ltd (ASX:RAC, OTC:RAONF) has taken another key step toward a Phase 1 trial in solid tumour patients using RC220 bisantrene by submitting an application for an ethics and regulatory package to Bellberry Human Research Ethics Committee (HREC) for approval. Read the full article here. Watch the interview with CEO and MD Dr Daniel Tillett.

Race CEO Dr Daniel Tillett joins Proactive’s Tylah Tully to discuss the FTO drug discovery program the company has concluded at Monash University’s Fragment Platform (MFP). Watch the full interview below and for the full news report via this link.

CEO and MD Dr Daniel Tillett joined ausbiz post the release of September Quarterly Activity Report, reaffirming the company’s strong funding position, clinical pipeline, and noting changes in the Board and Management team. Watch the full interview via this link.